nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—CYP2C8—Mometasone—systemic scleroderma	0.242	0.592	CbGbCtD
Trametinib—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.0961	0.236	CbGbCtD
Trametinib—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.039	0.0956	CbGbCtD
Trametinib—CYP3A4—Prednisone—systemic scleroderma	0.0312	0.0764	CbGbCtD
Trametinib—MAP2K1—TSLP Signaling Pathway—TNFSF4—systemic scleroderma	0.00624	0.0334	CbGpPWpGaD
Trametinib—MAP2K1—Signaling events mediated by focal adhesion kinase—GIT2—systemic scleroderma	0.00569	0.0304	CbGpPWpGaD
Trametinib—MAP2K1—connective tissue—systemic scleroderma	0.00488	0.13	CbGeAlD
Trametinib—MAP2K1—smooth muscle tissue—systemic scleroderma	0.00447	0.119	CbGeAlD
Trametinib—MAP2K1—skin of body—systemic scleroderma	0.00441	0.118	CbGeAlD
Trametinib—MAP2K2—Integrin-mediated Cell Adhesion—GIT2—systemic scleroderma	0.00409	0.0219	CbGpPWpGaD
Trametinib—MAP2K2—smooth muscle tissue—systemic scleroderma	0.00393	0.105	CbGeAlD
Trametinib—MAP2K2—skin of body—systemic scleroderma	0.00388	0.104	CbGeAlD
Trametinib—MAP2K1—Integrin-mediated Cell Adhesion—GIT2—systemic scleroderma	0.00383	0.0205	CbGpPWpGaD
Trametinib—MAP2K1—digestive system—systemic scleroderma	0.00353	0.0942	CbGeAlD
Trametinib—MAP2K1—IFN-gamma pathway—SMAD7—systemic scleroderma	0.00352	0.0188	CbGpPWpGaD
Trametinib—MAP2K1—FOXM1 transcription factor network—CENPA—systemic scleroderma	0.00314	0.0168	CbGpPWpGaD
Trametinib—MAP2K2—digestive system—systemic scleroderma	0.00311	0.0829	CbGeAlD
Trametinib—MAP2K2—tendon—systemic scleroderma	0.00296	0.0789	CbGeAlD
Trametinib—MAP2K1—lung—systemic scleroderma	0.00295	0.0787	CbGeAlD
Trametinib—MAP2K2—GMCSF-mediated signaling events—IRF8—systemic scleroderma	0.00281	0.015	CbGpPWpGaD
Trametinib—MAP2K1—GMCSF-mediated signaling events—IRF8—systemic scleroderma	0.00263	0.0141	CbGpPWpGaD
Trametinib—MAP2K2—lung—systemic scleroderma	0.00259	0.0693	CbGeAlD
Trametinib—MAP2K2—TSLP Signaling Pathway—STAT4—systemic scleroderma	0.00204	0.0109	CbGpPWpGaD
Trametinib—MAP2K2—Endothelins—COL1A2—systemic scleroderma	0.00202	0.0108	CbGpPWpGaD
Trametinib—MAP2K1—TSLP Signaling Pathway—STAT4—systemic scleroderma	0.00191	0.0102	CbGpPWpGaD
Trametinib—MAP2K1—Endothelins—COL1A2—systemic scleroderma	0.00189	0.0101	CbGpPWpGaD
Trametinib—MAP2K1—Osteopontin Signaling—MMP9—systemic scleroderma	0.00177	0.00946	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signaling in naïve CD8+ T cells—CD247—systemic scleroderma	0.00177	0.00946	CbGpPWpGaD
Trametinib—MAP2K1—BCR signaling pathway—CSK—systemic scleroderma	0.00174	0.0093	CbGpPWpGaD
Trametinib—MAP2K1—Endothelin Pathways—EDN1—systemic scleroderma	0.00172	0.00918	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signaling in naïve CD8+ T cells—CD247—systemic scleroderma	0.00166	0.00885	CbGpPWpGaD
Trametinib—MAP2K2—Bladder Cancer—MMP1—systemic scleroderma	0.00162	0.00867	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signaling in naïve CD8+ T cells—STAT4—systemic scleroderma	0.00156	0.00833	CbGpPWpGaD
Trametinib—MAP2K2—TGF-beta Signaling Pathway—SMAD7—systemic scleroderma	0.00153	0.0082	CbGpPWpGaD
Trametinib—MAP2K1—Bladder Cancer—MMP1—systemic scleroderma	0.00152	0.00812	CbGpPWpGaD
Trametinib—MAP2K1—Interleukin-1 signaling—IL1A—systemic scleroderma	0.00146	0.00783	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signaling in naïve CD8+ T cells—STAT4—systemic scleroderma	0.00146	0.00779	CbGpPWpGaD
Trametinib—MAP2K1—TGF-beta Signaling Pathway—SMAD7—systemic scleroderma	0.00144	0.00767	CbGpPWpGaD
Trametinib—MAP2K2—TCR Signaling Pathway—CD247—systemic scleroderma	0.00138	0.00738	CbGpPWpGaD
Trametinib—MAP2K2—Structural Pathway of Interleukin 1 (IL-1)—IL1A—systemic scleroderma	0.00138	0.00735	CbGpPWpGaD
Trametinib—MAP2K2—Integrin-mediated Cell Adhesion—CSK—systemic scleroderma	0.00135	0.00721	CbGpPWpGaD
Trametinib—MAP2K2—Cellular roles of Anthrax toxin—IL1B—systemic scleroderma	0.00132	0.00704	CbGpPWpGaD
Trametinib—MAP2K2—Toll-like Receptor Signaling Pathway—IRF5—systemic scleroderma	0.00131	0.00699	CbGpPWpGaD
Trametinib—MAP2K1—TCR Signaling Pathway—CD247—systemic scleroderma	0.00129	0.0069	CbGpPWpGaD
Trametinib—MAP2K1—Structural Pathway of Interleukin 1 (IL-1)—IL1A—systemic scleroderma	0.00129	0.00688	CbGpPWpGaD
Trametinib—MAP2K2—Integrin-mediated Cell Adhesion—ITGAM—systemic scleroderma	0.00127	0.00678	CbGpPWpGaD
Trametinib—MAP2K1—Integrin-mediated Cell Adhesion—CSK—systemic scleroderma	0.00126	0.00675	CbGpPWpGaD
Trametinib—MAP2K1—Cellular roles of Anthrax toxin—IL1B—systemic scleroderma	0.00123	0.00659	CbGpPWpGaD
Trametinib—MAP2K1—Toll-like Receptor Signaling Pathway—IRF5—systemic scleroderma	0.00122	0.00654	CbGpPWpGaD
Trametinib—MAP2K2—IL-1 signaling pathway—IL1A—systemic scleroderma	0.00121	0.00649	CbGpPWpGaD
Trametinib—MAP2K2—B Cell Receptor Signaling Pathway—BLK—systemic scleroderma	0.0012	0.00643	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.0012	0.0064	CbGpPWpGaD
Trametinib—MAP2K1—Senescence and Autophagy in Cancer—IRF5—systemic scleroderma	0.00119	0.00639	CbGpPWpGaD
Trametinib—MAP2K1—Integrin-mediated Cell Adhesion—ITGAM—systemic scleroderma	0.00119	0.00635	CbGpPWpGaD
Trametinib—MAP2K2—GMCSF-mediated signaling events—CCL2—systemic scleroderma	0.00115	0.00612	CbGpPWpGaD
Trametinib—MAP2K1—IL-1 signaling pathway—IL1A—systemic scleroderma	0.00114	0.00607	CbGpPWpGaD
Trametinib—MAP2K2—PDGFR-beta signaling pathway—CSK—systemic scleroderma	0.00113	0.00603	CbGpPWpGaD
Trametinib—MAP2K1—B Cell Receptor Signaling Pathway—BLK—systemic scleroderma	0.00113	0.00602	CbGpPWpGaD
Trametinib—MAP2K2—TGF-beta Signaling Pathway—COL1A2—systemic scleroderma	0.00112	0.00598	CbGpPWpGaD
Trametinib—MAP2K2—Endothelins—EDN1—systemic scleroderma	0.0011	0.00585	CbGpPWpGaD
Trametinib—MAP2K2—Toll Like Receptor 4 (TLR4) Cascade—ITGAM—systemic scleroderma	0.00108	0.00578	CbGpPWpGaD
Trametinib—MAP2K1—GMCSF-mediated signaling events—CCL2—systemic scleroderma	0.00107	0.00573	CbGpPWpGaD
Trametinib—MAP2K1—PDGFR-beta signaling pathway—CSK—systemic scleroderma	0.00106	0.00565	CbGpPWpGaD
Trametinib—MAP2K1—TGF-beta Signaling Pathway—COL1A2—systemic scleroderma	0.00105	0.0056	CbGpPWpGaD
Trametinib—MAP2K1—Endothelin Pathways—NOS3—systemic scleroderma	0.00105	0.0056	CbGpPWpGaD
Trametinib—MAP2K1—Endothelins—EDN1—systemic scleroderma	0.00102	0.00548	CbGpPWpGaD
Trametinib—MAP2K2—Regulation of toll-like receptor signaling pathway—IRF5—systemic scleroderma	0.00102	0.00545	CbGpPWpGaD
Trametinib—MAP2K1—Toll Like Receptor 4 (TLR4) Cascade—ITGAM—systemic scleroderma	0.00101	0.00541	CbGpPWpGaD
Trametinib—MAP2K2—PDGFR-beta signaling pathway—BLK—systemic scleroderma	0.000982	0.00525	CbGpPWpGaD
Trametinib—MAP2K2—Regulation of Actin Cytoskeleton—CSK—systemic scleroderma	0.000981	0.00524	CbGpPWpGaD
Trametinib—MAP2K2—Toll-Like Receptors Cascades—ITGAM—systemic scleroderma	0.000964	0.00515	CbGpPWpGaD
Trametinib—MAP2K1—Regulation of toll-like receptor signaling pathway—IRF5—systemic scleroderma	0.000955	0.0051	CbGpPWpGaD
Trametinib—MAP2K1—FOXM1 transcription factor network—MMP2—systemic scleroderma	0.000922	0.00493	CbGpPWpGaD
Trametinib—MAP2K2—Endothelins—MMP1—systemic scleroderma	0.00092	0.00492	CbGpPWpGaD
Trametinib—MAP2K1—PDGFR-beta signaling pathway—BLK—systemic scleroderma	0.000919	0.00491	CbGpPWpGaD
Trametinib—MAP2K1—Regulation of Actin Cytoskeleton—CSK—systemic scleroderma	0.000918	0.00491	CbGpPWpGaD
Trametinib—MAP2K2—EGF/EGFR Signaling Pathway—CSK—systemic scleroderma	0.000918	0.0049	CbGpPWpGaD
Trametinib—MAP2K2—Regulation of toll-like receptor signaling pathway—TNFAIP3—systemic scleroderma	0.000913	0.00488	CbGpPWpGaD
Trametinib—MAP2K1—Toll-Like Receptors Cascades—ITGAM—systemic scleroderma	0.000902	0.00482	CbGpPWpGaD
Trametinib—MAP2K2—Oncostatin M Signaling Pathway—MMP1—systemic scleroderma	0.000898	0.0048	CbGpPWpGaD
Trametinib—MAP2K2—Focal Adhesion—RHOB—systemic scleroderma	0.000887	0.00474	CbGpPWpGaD
Trametinib—MAP2K2—MicroRNAs in cardiomyocyte hypertrophy—EDN1—systemic scleroderma	0.00087	0.00465	CbGpPWpGaD
Trametinib—MAP2K1—Endothelins—MMP1—systemic scleroderma	0.000861	0.0046	CbGpPWpGaD
Trametinib—MAP2K1—EGF/EGFR Signaling Pathway—CSK—systemic scleroderma	0.000859	0.00459	CbGpPWpGaD
Trametinib—MAP2K1—Regulation of toll-like receptor signaling pathway—TNFAIP3—systemic scleroderma	0.000854	0.00457	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—CSK—systemic scleroderma	0.000847	0.00453	CbGpPWpGaD
Trametinib—MAP2K1—Oncostatin M Signaling Pathway—MMP1—systemic scleroderma	0.00084	0.00449	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—CSK—systemic scleroderma	0.00084	0.00449	CbGpPWpGaD
Trametinib—MAP2K2—Focal Adhesion—COL1A2—systemic scleroderma	0.000836	0.00447	CbGpPWpGaD
Trametinib—MAP2K2—IL-1 signaling pathway—CCL2—systemic scleroderma	0.000835	0.00446	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—RHOB—systemic scleroderma	0.00083	0.00443	CbGpPWpGaD
Trametinib—MAP2K2—TCR Signaling Pathway—IL1A—systemic scleroderma	0.000818	0.00437	CbGpPWpGaD
Trametinib—MAP2K1—MicroRNAs in cardiomyocyte hypertrophy—EDN1—systemic scleroderma	0.000814	0.00435	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—CSK—systemic scleroderma	0.000793	0.00424	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—CSK—systemic scleroderma	0.000786	0.0042	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—COL1A2—systemic scleroderma	0.000783	0.00418	CbGpPWpGaD
Trametinib—MAP2K1—IL-1 signaling pathway—CCL2—systemic scleroderma	0.000781	0.00417	CbGpPWpGaD
Trametinib—MAP2K1—TCR Signaling Pathway—IL1A—systemic scleroderma	0.000766	0.00409	CbGpPWpGaD
Trametinib—MAP2K1—Interleukin-1 signaling—IL1B—systemic scleroderma	0.000764	0.00408	CbGpPWpGaD
Trametinib—MAP2K2—Focal Adhesion—ITGAM—systemic scleroderma	0.000759	0.00406	CbGpPWpGaD
Trametinib—MAP2K2—Oncostatin M Signaling Pathway—CCL2—systemic scleroderma	0.00073	0.0039	CbGpPWpGaD
Trametinib—CYP3A4—digestive system—systemic scleroderma	0.000728	0.0195	CbGeAlD
Trametinib—MAP2K1—IFN-gamma pathway—IL1B—systemic scleroderma	0.000721	0.00385	CbGpPWpGaD
Trametinib—MAP2K2—SHP2 signaling—NOS3—systemic scleroderma	0.000713	0.00381	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—ITGAM—systemic scleroderma	0.000711	0.0038	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by Interleukins—IL1A—systemic scleroderma	0.000707	0.00378	CbGpPWpGaD
Trametinib—MAP2K2—Focal Adhesion—BLK—systemic scleroderma	0.000703	0.00376	CbGpPWpGaD
Trametinib—MAP2K1—Oncostatin M Signaling Pathway—CCL2—systemic scleroderma	0.000683	0.00365	CbGpPWpGaD
Trametinib—MAP2K1—Senescence and Autophagy in Cancer—IL1A—systemic scleroderma	0.000677	0.00362	CbGpPWpGaD
Trametinib—MAP2K1—SHP2 signaling—NOS3—systemic scleroderma	0.000667	0.00356	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by Interleukins—IL1A—systemic scleroderma	0.000662	0.00354	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—BLK—systemic scleroderma	0.000657	0.00351	CbGpPWpGaD
Trametinib—MAP2K1—AGE/RAGE pathway—MMP2—systemic scleroderma	0.000642	0.00343	CbGpPWpGaD
Trametinib—MAP2K2—IL-1 signaling pathway—IL1B—systemic scleroderma	0.000633	0.00338	CbGpPWpGaD
Trametinib—MAP2K2—Signaling events mediated by VEGFR1 and VEGFR2—NOS3—systemic scleroderma	0.000628	0.00335	CbGpPWpGaD
Trametinib—MAP2K1—AGE/RAGE pathway—NOS3—systemic scleroderma	0.000601	0.00321	CbGpPWpGaD
Trametinib—MAP2K1—IL-1 signaling pathway—IL1B—systemic scleroderma	0.000592	0.00316	CbGpPWpGaD
Trametinib—MAP2K2—Interleukin-11 Signaling Pathway—TGFB1—systemic scleroderma	0.000588	0.00314	CbGpPWpGaD
Trametinib—MAP2K1—Signaling events mediated by VEGFR1 and VEGFR2—NOS3—systemic scleroderma	0.000587	0.00314	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—IRF5—systemic scleroderma	0.000583	0.00311	CbGpPWpGaD
Trametinib—MAP2K2—Leptin signaling pathway—NOS3—systemic scleroderma	0.00058	0.0031	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—RHOB—systemic scleroderma	0.000579	0.00309	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—IRF8—systemic scleroderma	0.000557	0.00298	CbGpPWpGaD
Trametinib—MAP2K1—Interleukin-11 Signaling Pathway—TGFB1—systemic scleroderma	0.00055	0.00294	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—IRF5—systemic scleroderma	0.000545	0.00291	CbGpPWpGaD
Trametinib—MAP2K1—Leptin signaling pathway—NOS3—systemic scleroderma	0.000543	0.0029	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—RHOB—systemic scleroderma	0.000541	0.00289	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—IRF8—systemic scleroderma	0.000521	0.00278	CbGpPWpGaD
Trametinib—MAP2K2—TGF-beta Signaling Pathway—MMP1—systemic scleroderma	0.000509	0.00272	CbGpPWpGaD
Trametinib—MAP2K1—IL-3 Signaling Pathway—TGFB1—systemic scleroderma	0.000505	0.0027	CbGpPWpGaD
Trametinib—MAP2K2—MAPK Signaling Pathway—IL1A—systemic scleroderma	0.000497	0.00265	CbGpPWpGaD
Trametinib—MAP2K2—Leptin signaling pathway—IL1B—systemic scleroderma	0.000494	0.00264	CbGpPWpGaD
Trametinib—MAP2K2—Cardiac Hypertrophic Response—TGFB1—systemic scleroderma	0.000492	0.00263	CbGpPWpGaD
Trametinib—MAP2K1—AGE/RAGE pathway—MMP9—systemic scleroderma	0.000483	0.00258	CbGpPWpGaD
Trametinib—MAP2K1—TGF-beta Signaling Pathway—MMP1—systemic scleroderma	0.000477	0.00255	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—IL1A—systemic scleroderma	0.000465	0.00248	CbGpPWpGaD
Trametinib—MAP2K1—Leptin signaling pathway—IL1B—systemic scleroderma	0.000462	0.00247	CbGpPWpGaD
Trametinib—MAP2K1—Corticotropin-releasing hormone—NOS3—systemic scleroderma	0.000461	0.00246	CbGpPWpGaD
Trametinib—MAP2K1—Cardiac Hypertrophic Response—TGFB1—systemic scleroderma	0.00046	0.00246	CbGpPWpGaD
Trametinib—Gastrointestinal pain—Captopril—systemic scleroderma	0.000459	0.00125	CcSEcCtD
Trametinib—Asthenia—Mometasone—systemic scleroderma	0.000459	0.00125	CcSEcCtD
Trametinib—Eye disorder—Mycophenolate mofetil—systemic scleroderma	0.000459	0.00125	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.000458	0.00125	CcSEcCtD
Trametinib—Cardiac disorder—Mycophenolate mofetil—systemic scleroderma	0.000455	0.00124	CcSEcCtD
Trametinib—Nervous system disorder—Leflunomide—systemic scleroderma	0.000454	0.00124	CcSEcCtD
Trametinib—Thrombocytopenia—Leflunomide—systemic scleroderma	0.000453	0.00123	CcSEcCtD
Trametinib—Pruritus—Mometasone—systemic scleroderma	0.000453	0.00123	CcSEcCtD
Trametinib—Dry mouth—Mycophenolic acid—systemic scleroderma	0.000451	0.00123	CcSEcCtD
Trametinib—Anaemia—Lisinopril—systemic scleroderma	0.000451	0.00123	CcSEcCtD
Trametinib—Skin disorder—Leflunomide—systemic scleroderma	0.00045	0.00122	CcSEcCtD
Trametinib—Hyperhidrosis—Leflunomide—systemic scleroderma	0.000448	0.00122	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.000447	0.00122	CcSEcCtD
Trametinib—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.000445	0.00121	CcSEcCtD
Trametinib—Abdominal pain—Captopril—systemic scleroderma	0.000444	0.00121	CcSEcCtD
Trametinib—Body temperature increased—Captopril—systemic scleroderma	0.000444	0.00121	CcSEcCtD
Trametinib—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000442	0.0012	CcSEcCtD
Trametinib—Oedema—Mycophenolic acid—systemic scleroderma	0.000442	0.0012	CcSEcCtD
Trametinib—Dry skin—Prednisone—systemic scleroderma	0.000441	0.0012	CcSEcCtD
Trametinib—Nausea—Pentoxifylline—systemic scleroderma	0.00044	0.0012	CcSEcCtD
Trametinib—Chills—Mycophenolate mofetil—systemic scleroderma	0.00044	0.0012	CcSEcCtD
Trametinib—Infection—Mycophenolic acid—systemic scleroderma	0.000439	0.00119	CcSEcCtD
Trametinib—Arrhythmia—Mycophenolate mofetil—systemic scleroderma	0.000438	0.00119	CcSEcCtD
Trametinib—Diarrhoea—Mometasone—systemic scleroderma	0.000438	0.00119	CcSEcCtD
Trametinib—Hypokalaemia—Prednisone—systemic scleroderma	0.000438	0.00119	CcSEcCtD
Trametinib—MAP2K2—VEGFA-VEGFR2 Pathway—NOS3—systemic scleroderma	0.000437	0.00233	CbGpPWpGaD
Trametinib—Leukopenia—Lisinopril—systemic scleroderma	0.000436	0.00119	CcSEcCtD
Trametinib—Renal failure acute—Methotrexate—systemic scleroderma	0.000435	0.00118	CcSEcCtD
Trametinib—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000433	0.00118	CcSEcCtD
Trametinib—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.000432	0.00118	CcSEcCtD
Trametinib—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.00043	0.00117	CcSEcCtD
Trametinib—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000429	0.00117	CcSEcCtD
Trametinib—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.000427	0.00116	CcSEcCtD
Trametinib—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.000427	0.00116	CcSEcCtD
Trametinib—MAP2K2—TCR Signaling Pathway—IL1B—systemic scleroderma	0.000427	0.00228	CbGpPWpGaD
Trametinib—Cough—Lisinopril—systemic scleroderma	0.000425	0.00116	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Prednisone—systemic scleroderma	0.000424	0.00115	CcSEcCtD
Trametinib—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000423	0.00115	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000422	0.00115	CcSEcCtD
Trametinib—Insomnia—Leflunomide—systemic scleroderma	0.000419	0.00114	CcSEcCtD
Trametinib—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.000418	0.00114	CcSEcCtD
Trametinib—Arthralgia—Lisinopril—systemic scleroderma	0.000415	0.00113	CcSEcCtD
Trametinib—Myalgia—Lisinopril—systemic scleroderma	0.000415	0.00113	CcSEcCtD
Trametinib—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000413	0.00112	CcSEcCtD
Trametinib—MAP2K2—Developmental Biology—RHOB—systemic scleroderma	0.000413	0.00221	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by VEGF—NOS3—systemic scleroderma	0.000412	0.0022	CbGpPWpGaD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000412	0.00112	CcSEcCtD
Trametinib—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.000411	0.00112	CcSEcCtD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	0.00041	0.00219	CbGpPWpGaD
Trametinib—MAP2K1—VEGFA-VEGFR2 Pathway—NOS3—systemic scleroderma	0.000409	0.00218	CbGpPWpGaD
Trametinib—Pancreatitis—Prednisone—systemic scleroderma	0.000407	0.00111	CcSEcCtD
Trametinib—Vomiting—Mometasone—systemic scleroderma	0.000407	0.00111	CcSEcCtD
Trametinib—Dry mouth—Lisinopril—systemic scleroderma	0.000406	0.0011	CcSEcCtD
Trametinib—Rash—Mometasone—systemic scleroderma	0.000403	0.0011	CcSEcCtD
Trametinib—Asthenia—Captopril—systemic scleroderma	0.000403	0.0011	CcSEcCtD
Trametinib—Dermatitis—Mometasone—systemic scleroderma	0.000403	0.0011	CcSEcCtD
Trametinib—Decreased appetite—Leflunomide—systemic scleroderma	0.000403	0.0011	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000402	0.00109	CcSEcCtD
Trametinib—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000401	0.00109	CcSEcCtD
Trametinib—Headache—Mometasone—systemic scleroderma	0.000401	0.00109	CcSEcCtD
Trametinib—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.0004	0.00109	CcSEcCtD
Trametinib—Insomnia—Mycophenolic acid—systemic scleroderma	0.0004	0.00109	CcSEcCtD
Trametinib—MAP2K1—TCR Signaling Pathway—IL1B—systemic scleroderma	0.000399	0.00213	CbGpPWpGaD
Trametinib—Fatigue—Leflunomide—systemic scleroderma	0.000399	0.00109	CcSEcCtD
Trametinib—Oedema—Lisinopril—systemic scleroderma	0.000398	0.00108	CcSEcCtD
Trametinib—Pruritus—Captopril—systemic scleroderma	0.000397	0.00108	CcSEcCtD
Trametinib—Constipation—Leflunomide—systemic scleroderma	0.000396	0.00108	CcSEcCtD
Trametinib—Infection—Lisinopril—systemic scleroderma	0.000395	0.00108	CcSEcCtD
Trametinib—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000395	0.00107	CcSEcCtD
Trametinib—Thrombocytopenia—Lisinopril—systemic scleroderma	0.00039	0.00106	CcSEcCtD
Trametinib—Neutropenia—Prednisone—systemic scleroderma	0.000389	0.00106	CcSEcCtD
Trametinib—Body temperature increased—Azathioprine—systemic scleroderma	0.000388	0.00105	CcSEcCtD
Trametinib—Abdominal pain—Azathioprine—systemic scleroderma	0.000388	0.00105	CcSEcCtD
Trametinib—Skin disorder—Lisinopril—systemic scleroderma	0.000386	0.00105	CcSEcCtD
Trametinib—MAP2K1—Developmental Biology—RHOB—systemic scleroderma	0.000386	0.00206	CbGpPWpGaD
Trametinib—MAP2K2—Toll-like Receptor Signaling Pathway—IL1B—systemic scleroderma	0.000386	0.00206	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by VEGF—NOS3—systemic scleroderma	0.000386	0.00206	CbGpPWpGaD
Trametinib—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000385	0.00105	CcSEcCtD
Trametinib—Diarrhoea—Captopril—systemic scleroderma	0.000384	0.00105	CcSEcCtD
Trametinib—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000384	0.00104	CcSEcCtD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	0.000384	0.00205	CbGpPWpGaD
Trametinib—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000382	0.00104	CcSEcCtD
Trametinib—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000381	0.00104	CcSEcCtD
Trametinib—Fatigue—Mycophenolic acid—systemic scleroderma	0.000381	0.00104	CcSEcCtD
Trametinib—Nausea—Mometasone—systemic scleroderma	0.00038	0.00103	CcSEcCtD
Trametinib—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000379	0.00103	CcSEcCtD
Trametinib—Constipation—Mycophenolic acid—systemic scleroderma	0.000378	0.00103	CcSEcCtD
Trametinib—Hyperglycaemia—Prednisone—systemic scleroderma	0.000375	0.00102	CcSEcCtD
Trametinib—Cough—Mycophenolate mofetil—systemic scleroderma	0.000373	0.00101	CcSEcCtD
Trametinib—Dizziness—Captopril—systemic scleroderma	0.000372	0.00101	CcSEcCtD
Trametinib—MAP2K2—Signaling by Interleukins—IL1B—systemic scleroderma	0.000369	0.00197	CbGpPWpGaD
Trametinib—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000369	0.001	CcSEcCtD
Trametinib—Body temperature increased—Leflunomide—systemic scleroderma	0.000366	0.000996	CcSEcCtD
Trametinib—Abdominal pain—Leflunomide—systemic scleroderma	0.000366	0.000996	CcSEcCtD
Trametinib—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000364	0.000989	CcSEcCtD
Trametinib—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000364	0.000989	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000362	0.000986	CcSEcCtD
Trametinib—MAP2K1—Toll-like Receptor Signaling Pathway—IL1B—systemic scleroderma	0.000361	0.00193	CbGpPWpGaD
Trametinib—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000361	0.000983	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000361	0.000983	CcSEcCtD
Trametinib—Insomnia—Lisinopril—systemic scleroderma	0.00036	0.000979	CcSEcCtD
Trametinib—Vomiting—Captopril—systemic scleroderma	0.000357	0.000972	CcSEcCtD
Trametinib—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000356	0.000968	CcSEcCtD
Trametinib—Rash—Captopril—systemic scleroderma	0.000354	0.000964	CcSEcCtD
Trametinib—Dermatitis—Captopril—systemic scleroderma	0.000354	0.000963	CcSEcCtD
Trametinib—MAP2K1—Senescence and Autophagy in Cancer—IL1B—systemic scleroderma	0.000353	0.00189	CbGpPWpGaD
Trametinib—Headache—Captopril—systemic scleroderma	0.000352	0.000958	CcSEcCtD
Trametinib—MAP2K2—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—systemic scleroderma	0.000351	0.00187	CbGpPWpGaD
Trametinib—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000349	0.00095	CcSEcCtD
Trametinib—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000349	0.00095	CcSEcCtD
Trametinib—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000349	0.000948	CcSEcCtD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—HLA-DQB1—systemic scleroderma	0.000348	0.00186	CbGpPWpGaD
Trametinib—Infection—Mycophenolate mofetil—systemic scleroderma	0.000346	0.000942	CcSEcCtD
Trametinib—Decreased appetite—Lisinopril—systemic scleroderma	0.000346	0.000941	CcSEcCtD
Trametinib—MAP2K1—Signaling by Interleukins—IL1B—systemic scleroderma	0.000345	0.00184	CbGpPWpGaD
Trametinib—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000343	0.000935	CcSEcCtD
Trametinib—Fatigue—Lisinopril—systemic scleroderma	0.000343	0.000933	CcSEcCtD
Trametinib—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000342	0.00093	CcSEcCtD
Trametinib—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000341	0.000929	CcSEcCtD
Trametinib—Pancreatitis—Methotrexate—systemic scleroderma	0.00034	0.000926	CcSEcCtD
Trametinib—Constipation—Lisinopril—systemic scleroderma	0.00034	0.000926	CcSEcCtD
Trametinib—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000339	0.000921	CcSEcCtD
Trametinib—Bradycardia—Prednisone—systemic scleroderma	0.000339	0.000921	CcSEcCtD
Trametinib—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000337	0.000917	CcSEcCtD
Trametinib—Diarrhoea—Azathioprine—systemic scleroderma	0.000335	0.000913	CcSEcCtD
Trametinib—Haemoglobin—Prednisone—systemic scleroderma	0.000334	0.00091	CcSEcCtD
Trametinib—Nausea—Captopril—systemic scleroderma	0.000334	0.000908	CcSEcCtD
Trametinib—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000333	0.000906	CcSEcCtD
Trametinib—Haemorrhage—Prednisone—systemic scleroderma	0.000333	0.000905	CcSEcCtD
Trametinib—Asthenia—Leflunomide—systemic scleroderma	0.000332	0.000904	CcSEcCtD
Trametinib—MAP2K2—TCR Signaling Pathway—TGFB1—systemic scleroderma	0.000332	0.00177	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—IL1A—systemic scleroderma	0.00033	0.00176	CbGpPWpGaD
Trametinib—MAP2K1—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—systemic scleroderma	0.000328	0.00175	CbGpPWpGaD
Trametinib—Pruritus—Leflunomide—systemic scleroderma	0.000328	0.000891	CcSEcCtD
Trametinib—Connective tissue disorder—Prednisone—systemic scleroderma	0.000327	0.000889	CcSEcCtD
Trametinib—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000325	0.000885	CcSEcCtD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—HLA-DQB1—systemic scleroderma	0.000325	0.00174	CbGpPWpGaD
Trametinib—Neutropenia—Methotrexate—systemic scleroderma	0.000325	0.000883	CcSEcCtD
Trametinib—Dizziness—Azathioprine—systemic scleroderma	0.000324	0.000882	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000318	0.000864	CcSEcCtD
Trametinib—Asthenia—Mycophenolic acid—systemic scleroderma	0.000317	0.000862	CcSEcCtD
Trametinib—Diarrhoea—Leflunomide—systemic scleroderma	0.000317	0.000862	CcSEcCtD
Trametinib—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000315	0.000858	CcSEcCtD
Trametinib—Body temperature increased—Lisinopril—systemic scleroderma	0.000315	0.000856	CcSEcCtD
Trametinib—Abdominal pain—Lisinopril—systemic scleroderma	0.000315	0.000856	CcSEcCtD
Trametinib—MAP2K2—EGF/EGFR Signaling Pathway—NOS3—systemic scleroderma	0.000313	0.00167	CbGpPWpGaD
Trametinib—Pruritus—Mycophenolic acid—systemic scleroderma	0.000313	0.00085	CcSEcCtD
Trametinib—MAP2K2—Innate Immune System—CD247—systemic scleroderma	0.000312	0.00167	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—ITGAM—systemic scleroderma	0.000312	0.00167	CbGpPWpGaD
Trametinib—Vomiting—Azathioprine—systemic scleroderma	0.000312	0.000848	CcSEcCtD
Trametinib—Eye disorder—Prednisone—systemic scleroderma	0.000311	0.000846	CcSEcCtD
Trametinib—MAP2K1—TCR Signaling Pathway—TGFB1—systemic scleroderma	0.00031	0.00166	CbGpPWpGaD
Trametinib—Infestation NOS—Methotrexate—systemic scleroderma	0.00031	0.000842	CcSEcCtD
Trametinib—Infestation—Methotrexate—systemic scleroderma	0.00031	0.000842	CcSEcCtD
Trametinib—Rash—Azathioprine—systemic scleroderma	0.000309	0.000841	CcSEcCtD
Trametinib—Dermatitis—Azathioprine—systemic scleroderma	0.000309	0.00084	CcSEcCtD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—IL1A—systemic scleroderma	0.000309	0.00165	CbGpPWpGaD
Trametinib—Headache—Azathioprine—systemic scleroderma	0.000307	0.000836	CcSEcCtD
Trametinib—Dizziness—Leflunomide—systemic scleroderma	0.000306	0.000833	CcSEcCtD
Trametinib—MAP2K1—Corticotropin-releasing hormone—TGFB1—systemic scleroderma	0.000305	0.00163	CbGpPWpGaD
Trametinib—Renal failure—Methotrexate—systemic scleroderma	0.000304	0.000828	CcSEcCtD
Trametinib—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000303	0.000824	CcSEcCtD
Trametinib—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000302	0.000822	CcSEcCtD
Trametinib—Stomatitis—Methotrexate—systemic scleroderma	0.000302	0.000821	CcSEcCtD
Trametinib—Angiopathy—Prednisone—systemic scleroderma	0.000302	0.000821	CcSEcCtD
Trametinib—MAP2K2—Regulation of toll-like receptor signaling pathway—IL1B—systemic scleroderma	0.000301	0.00161	CbGpPWpGaD
Trametinib—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000301	0.000819	CcSEcCtD
Trametinib—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000298	0.000811	CcSEcCtD
Trametinib—Arrhythmia—Prednisone—systemic scleroderma	0.000297	0.000808	CcSEcCtD
Trametinib—Haematuria—Methotrexate—systemic scleroderma	0.000295	0.000803	CcSEcCtD
Trametinib—Vomiting—Leflunomide—systemic scleroderma	0.000294	0.000801	CcSEcCtD
Trametinib—MAP2K1—EGF/EGFR Signaling Pathway—NOS3—systemic scleroderma	0.000293	0.00157	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—TNFAIP3—systemic scleroderma	0.000292	0.00156	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—ITGAM—systemic scleroderma	0.000292	0.00156	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—CD247—systemic scleroderma	0.000292	0.00156	CbGpPWpGaD
Trametinib—Dizziness—Mycophenolic acid—systemic scleroderma	0.000292	0.000795	CcSEcCtD
Trametinib—Epistaxis—Methotrexate—systemic scleroderma	0.000292	0.000795	CcSEcCtD
Trametinib—Rash—Leflunomide—systemic scleroderma	0.000292	0.000794	CcSEcCtD
Trametinib—Dermatitis—Leflunomide—systemic scleroderma	0.000292	0.000794	CcSEcCtD
Trametinib—Mental disorder—Prednisone—systemic scleroderma	0.000291	0.000793	CcSEcCtD
Trametinib—Nausea—Azathioprine—systemic scleroderma	0.000291	0.000792	CcSEcCtD
Trametinib—Headache—Leflunomide—systemic scleroderma	0.00029	0.000789	CcSEcCtD
Trametinib—Erythema—Prednisone—systemic scleroderma	0.00029	0.000788	CcSEcCtD
Trametinib—Malnutrition—Prednisone—systemic scleroderma	0.00029	0.000788	CcSEcCtD
Trametinib—Asthenia—Lisinopril—systemic scleroderma	0.000285	0.000777	CcSEcCtD
Trametinib—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000285	0.000776	CcSEcCtD
Trametinib—MAP2K1—Regulation of toll-like receptor signaling pathway—IL1B—systemic scleroderma	0.000282	0.00151	CbGpPWpGaD
Trametinib—Pruritus—Lisinopril—systemic scleroderma	0.000281	0.000766	CcSEcCtD
Trametinib—MAP2K2—Signaling by SCF-KIT—MMP9—systemic scleroderma	0.000281	0.0015	CbGpPWpGaD
Trametinib—Vomiting—Mycophenolic acid—systemic scleroderma	0.000281	0.000764	CcSEcCtD
Trametinib—Haemoglobin—Methotrexate—systemic scleroderma	0.000279	0.00076	CcSEcCtD
Trametinib—Rash—Mycophenolic acid—systemic scleroderma	0.000279	0.000758	CcSEcCtD
Trametinib—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000278	0.000757	CcSEcCtD
Trametinib—Haemorrhage—Methotrexate—systemic scleroderma	0.000278	0.000756	CcSEcCtD
Trametinib—Headache—Mycophenolic acid—systemic scleroderma	0.000277	0.000753	CcSEcCtD
Trametinib—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000276	0.00075	CcSEcCtD
Trametinib—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000276	0.00075	CcSEcCtD
Trametinib—Nausea—Leflunomide—systemic scleroderma	0.000275	0.000748	CcSEcCtD
Trametinib—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000275	0.000747	CcSEcCtD
Trametinib—MAP2K1—Senescence and Autophagy in Cancer—TGFB1—systemic scleroderma	0.000274	0.00147	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—TNFAIP3—systemic scleroderma	0.000274	0.00146	CbGpPWpGaD
Trametinib—Vision blurred—Prednisone—systemic scleroderma	0.000273	0.000742	CcSEcCtD
Trametinib—Urethral disorder—Methotrexate—systemic scleroderma	0.000272	0.000741	CcSEcCtD
Trametinib—Diarrhoea—Lisinopril—systemic scleroderma	0.000272	0.000741	CcSEcCtD
Trametinib—Anaemia—Prednisone—systemic scleroderma	0.000268	0.000728	CcSEcCtD
Trametinib—Dizziness—Lisinopril—systemic scleroderma	0.000263	0.000716	CcSEcCtD
Trametinib—MAP2K1—Signaling by SCF-KIT—MMP9—systemic scleroderma	0.000263	0.0014	CbGpPWpGaD
Trametinib—Nausea—Mycophenolic acid—systemic scleroderma	0.000262	0.000714	CcSEcCtD
Trametinib—Eye disorder—Methotrexate—systemic scleroderma	0.00026	0.000707	CcSEcCtD
Trametinib—MAP2K2—MAPK Signaling Pathway—IL1B—systemic scleroderma	0.000259	0.00138	CbGpPWpGaD
Trametinib—Cardiac disorder—Methotrexate—systemic scleroderma	0.000258	0.000702	CcSEcCtD
Trametinib—MAP2K2—Disease—SMAD7—systemic scleroderma	0.000254	0.00135	CbGpPWpGaD
Trametinib—Vomiting—Lisinopril—systemic scleroderma	0.000253	0.000688	CcSEcCtD
Trametinib—Angiopathy—Methotrexate—systemic scleroderma	0.000252	0.000686	CcSEcCtD
Trametinib—Rash—Lisinopril—systemic scleroderma	0.000251	0.000683	CcSEcCtD
Trametinib—Dermatitis—Lisinopril—systemic scleroderma	0.000251	0.000682	CcSEcCtD
Trametinib—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000251	0.000682	CcSEcCtD
Trametinib—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.00025	0.00068	CcSEcCtD
Trametinib—Hypertension—Prednisone—systemic scleroderma	0.00025	0.00068	CcSEcCtD
Trametinib—Chills—Methotrexate—systemic scleroderma	0.000249	0.000679	CcSEcCtD
Trametinib—Headache—Lisinopril—systemic scleroderma	0.000249	0.000678	CcSEcCtD
Trametinib—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000247	0.000671	CcSEcCtD
Trametinib—Arthralgia—Prednisone—systemic scleroderma	0.000246	0.000671	CcSEcCtD
Trametinib—Myalgia—Prednisone—systemic scleroderma	0.000246	0.000671	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000245	0.000666	CcSEcCtD
Trametinib—MAP2K2—TGF-beta Signaling Pathway—TGFB1—systemic scleroderma	0.000244	0.0013	CbGpPWpGaD
Trametinib—Mental disorder—Methotrexate—systemic scleroderma	0.000244	0.000663	CcSEcCtD
Trametinib—MAP2K1—MAPK Signaling Pathway—IL1B—systemic scleroderma	0.000242	0.0013	CbGpPWpGaD
Trametinib—Malnutrition—Methotrexate—systemic scleroderma	0.000242	0.000658	CcSEcCtD
Trametinib—Erythema—Methotrexate—systemic scleroderma	0.000242	0.000658	CcSEcCtD
Trametinib—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000239	0.000649	CcSEcCtD
Trametinib—MAP2K1—Disease—SMAD7—systemic scleroderma	0.000237	0.00127	CbGpPWpGaD
Trametinib—Dysgeusia—Methotrexate—systemic scleroderma	0.000237	0.000645	CcSEcCtD
Trametinib—Nausea—Lisinopril—systemic scleroderma	0.000236	0.000643	CcSEcCtD
Trametinib—Oedema—Prednisone—systemic scleroderma	0.000236	0.000643	CcSEcCtD
Trametinib—Infection—Prednisone—systemic scleroderma	0.000235	0.000639	CcSEcCtD
Trametinib—Back pain—Methotrexate—systemic scleroderma	0.000234	0.000637	CcSEcCtD
Trametinib—MAP2K2—Signaling by GPCR—RHOB—systemic scleroderma	0.000232	0.00124	CbGpPWpGaD
Trametinib—MAP2K2—Disease—TGFBI—systemic scleroderma	0.000232	0.00124	CbGpPWpGaD
Trametinib—Nervous system disorder—Prednisone—systemic scleroderma	0.000232	0.00063	CcSEcCtD
Trametinib—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000231	0.000627	CcSEcCtD
Trametinib—Skin disorder—Prednisone—systemic scleroderma	0.00023	0.000624	CcSEcCtD
Trametinib—Hyperhidrosis—Prednisone—systemic scleroderma	0.000228	0.000622	CcSEcCtD
Trametinib—MAP2K1—TGF-beta Signaling Pathway—TGFB1—systemic scleroderma	0.000228	0.00122	CbGpPWpGaD
Trametinib—Vision blurred—Methotrexate—systemic scleroderma	0.000228	0.00062	CcSEcCtD
Trametinib—Anaemia—Methotrexate—systemic scleroderma	0.000224	0.000608	CcSEcCtD
Trametinib—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000222	0.000603	CcSEcCtD
Trametinib—Rash—Mycophenolate mofetil—systemic scleroderma	0.00022	0.000598	CcSEcCtD
Trametinib—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.00022	0.000597	CcSEcCtD
Trametinib—Headache—Mycophenolate mofetil—systemic scleroderma	0.000218	0.000594	CcSEcCtD
Trametinib—MAP2K1—Signaling by GPCR—RHOB—systemic scleroderma	0.000218	0.00116	CbGpPWpGaD
Trametinib—MAP2K1—Disease—TGFBI—systemic scleroderma	0.000217	0.00116	CbGpPWpGaD
Trametinib—Leukopenia—Methotrexate—systemic scleroderma	0.000217	0.000589	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000215	0.000586	CcSEcCtD
Trametinib—Insomnia—Prednisone—systemic scleroderma	0.000214	0.000581	CcSEcCtD
Trametinib—Cough—Methotrexate—systemic scleroderma	0.000211	0.000574	CcSEcCtD
Trametinib—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000207	0.000563	CcSEcCtD
Trametinib—Arthralgia—Methotrexate—systemic scleroderma	0.000206	0.00056	CcSEcCtD
Trametinib—Myalgia—Methotrexate—systemic scleroderma	0.000206	0.00056	CcSEcCtD
Trametinib—Decreased appetite—Prednisone—systemic scleroderma	0.000205	0.000559	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000205	0.000557	CcSEcCtD
Trametinib—Fatigue—Prednisone—systemic scleroderma	0.000204	0.000554	CcSEcCtD
Trametinib—Constipation—Prednisone—systemic scleroderma	0.000202	0.00055	CcSEcCtD
Trametinib—MAP2K2—MAPK Signaling Pathway—TGFB1—systemic scleroderma	0.000201	0.00108	CbGpPWpGaD
Trametinib—Infection—Methotrexate—systemic scleroderma	0.000196	0.000534	CcSEcCtD
Trametinib—Nervous system disorder—Methotrexate—systemic scleroderma	0.000194	0.000527	CcSEcCtD
Trametinib—MAP2K2—Immune System—CSK—systemic scleroderma	0.000193	0.00103	CbGpPWpGaD
Trametinib—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000193	0.000526	CcSEcCtD
Trametinib—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000193	0.000526	CcSEcCtD
Trametinib—MAP2K2—Axon guidance—MMP2—systemic scleroderma	0.000192	0.00103	CbGpPWpGaD
Trametinib—Skin disorder—Methotrexate—systemic scleroderma	0.000192	0.000522	CcSEcCtD
Trametinib—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000191	0.000519	CcSEcCtD
Trametinib—MAP2K2—Immune System—IRF5—systemic scleroderma	0.00019	0.00102	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—TGFB1—systemic scleroderma	0.000188	0.00101	CbGpPWpGaD
Trametinib—Body temperature increased—Prednisone—systemic scleroderma	0.000187	0.000508	CcSEcCtD
Trametinib—Abdominal pain—Prednisone—systemic scleroderma	0.000187	0.000508	CcSEcCtD
Trametinib—MAP2K2—Disease—HSPG2—systemic scleroderma	0.000185	0.000988	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IRF8—systemic scleroderma	0.000182	0.000972	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CD247—systemic scleroderma	0.000182	0.000972	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—ITGAM—systemic scleroderma	0.000182	0.000972	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CSK—systemic scleroderma	0.000181	0.000967	CbGpPWpGaD
Trametinib—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.00018	0.00049	CcSEcCtD
Trametinib—MAP2K1—Axon guidance—MMP2—systemic scleroderma	0.00018	0.000961	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CSK—systemic scleroderma	0.000179	0.000955	CbGpPWpGaD
Trametinib—Insomnia—Methotrexate—systemic scleroderma	0.000179	0.000486	CcSEcCtD
Trametinib—MAP2K1—Immune System—IRF5—systemic scleroderma	0.000178	0.000952	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—SMAD7—systemic scleroderma	0.000178	0.000949	CbGpPWpGaD
Trametinib—MAP2K1—Disease—HSPG2—systemic scleroderma	0.000173	0.000925	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	0.000172	0.00092	CbGpPWpGaD
Trametinib—Decreased appetite—Methotrexate—systemic scleroderma	0.000172	0.000467	CcSEcCtD
Trametinib—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.00017	0.000464	CcSEcCtD
Trametinib—MAP2K2—Immune System—TNFAIP3—systemic scleroderma	0.00017	0.00091	CbGpPWpGaD
Trametinib—Fatigue—Methotrexate—systemic scleroderma	0.00017	0.000463	CcSEcCtD
Trametinib—MAP2K1—Immune System—IRF8—systemic scleroderma	0.00017	0.000909	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CD247—systemic scleroderma	0.00017	0.000909	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—ITGAM—systemic scleroderma	0.00017	0.000909	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	0.00017	0.000908	CbGpPWpGaD
Trametinib—Asthenia—Prednisone—systemic scleroderma	0.00017	0.000461	CcSEcCtD
Trametinib—MAP2K2—Immune System—BLK—systemic scleroderma	0.000168	0.000899	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CD247—systemic scleroderma	0.000168	0.000897	CbGpPWpGaD
Trametinib—Pruritus—Prednisone—systemic scleroderma	0.000167	0.000455	CcSEcCtD
Trametinib—MAP2K1—Disease—CSK—systemic scleroderma	0.000167	0.000893	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SMAD7—systemic scleroderma	0.000166	0.000888	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000164	0.000875	CbGpPWpGaD
Trametinib—Diarrhoea—Prednisone—systemic scleroderma	0.000162	0.00044	CcSEcCtD
Trametinib—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000161	0.000439	CcSEcCtD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	0.000161	0.000861	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—TNFAIP3—systemic scleroderma	0.000159	0.000852	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—BLK—systemic scleroderma	0.000157	0.000841	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CD247—systemic scleroderma	0.000157	0.00084	CbGpPWpGaD
Trametinib—Dizziness—Prednisone—systemic scleroderma	0.000156	0.000425	CcSEcCtD
Trametinib—Abdominal pain—Methotrexate—systemic scleroderma	0.000156	0.000425	CcSEcCtD
Trametinib—Body temperature increased—Methotrexate—systemic scleroderma	0.000156	0.000425	CcSEcCtD
Trametinib—Vomiting—Prednisone—systemic scleroderma	0.00015	0.000409	CcSEcCtD
Trametinib—Rash—Prednisone—systemic scleroderma	0.000149	0.000405	CcSEcCtD
Trametinib—Dermatitis—Prednisone—systemic scleroderma	0.000149	0.000405	CcSEcCtD
Trametinib—Headache—Prednisone—systemic scleroderma	0.000148	0.000403	CcSEcCtD
Trametinib—MAP2K2—Axon guidance—MMP9—systemic scleroderma	0.000144	0.000772	CbGpPWpGaD
Trametinib—Asthenia—Methotrexate—systemic scleroderma	0.000142	0.000385	CcSEcCtD
Trametinib—Nausea—Prednisone—systemic scleroderma	0.00014	0.000382	CcSEcCtD
Trametinib—Pruritus—Methotrexate—systemic scleroderma	0.00014	0.00038	CcSEcCtD
Trametinib—MAP2K2—Immune System—CTLA4—systemic scleroderma	0.000138	0.000737	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—RHOB—systemic scleroderma	0.000137	0.000734	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—MMP2—systemic scleroderma	0.000137	0.000733	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—MMP9—systemic scleroderma	0.000135	0.000722	CbGpPWpGaD
Trametinib—Diarrhoea—Methotrexate—systemic scleroderma	0.000135	0.000368	CcSEcCtD
Trametinib—Dizziness—Methotrexate—systemic scleroderma	0.000131	0.000355	CcSEcCtD
Trametinib—MAP2K2—Signaling Pathways—HSPG2—systemic scleroderma	0.00013	0.000692	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CTLA4—systemic scleroderma	0.000129	0.000689	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—RHOB—systemic scleroderma	0.000128	0.000687	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—MMP2—systemic scleroderma	0.000128	0.000686	CbGpPWpGaD
Trametinib—Vomiting—Methotrexate—systemic scleroderma	0.000126	0.000342	CcSEcCtD
Trametinib—MAP2K2—Signaling Pathways—CSK—systemic scleroderma	0.000125	0.000668	CbGpPWpGaD
Trametinib—Rash—Methotrexate—systemic scleroderma	0.000125	0.000339	CcSEcCtD
Trametinib—Dermatitis—Methotrexate—systemic scleroderma	0.000124	0.000338	CcSEcCtD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.000124	0.000663	CbGpPWpGaD
Trametinib—Headache—Methotrexate—systemic scleroderma	0.000124	0.000337	CcSEcCtD
Trametinib—MAP2K1—Signaling Pathways—HSPG2—systemic scleroderma	0.000121	0.000648	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—EDN1—systemic scleroderma	0.000119	0.000634	CbGpPWpGaD
Trametinib—Nausea—Methotrexate—systemic scleroderma	0.000117	0.000319	CcSEcCtD
Trametinib—MAP2K1—Signaling Pathways—CSK—systemic scleroderma	0.000117	0.000625	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HLA-DQB1—systemic scleroderma	0.000114	0.000607	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—EDN1—systemic scleroderma	0.000111	0.000593	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL1A—systemic scleroderma	0.000108	0.000576	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CD40LG—systemic scleroderma	0.000107	0.000573	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HLA-DQB1—systemic scleroderma	0.000106	0.000568	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—MMP9—systemic scleroderma	0.000103	0.000551	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL1A—systemic scleroderma	0.000101	0.000539	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CD40LG—systemic scleroderma	0.0001	0.000536	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—MMP9—systemic scleroderma	9.64e-05	0.000515	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—TGFB1—systemic scleroderma	8.49e-05	0.000454	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CCL2—systemic scleroderma	8.11e-05	0.000434	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—TGFB1—systemic scleroderma	7.95e-05	0.000425	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CCL2—systemic scleroderma	7.59e-05	0.000406	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—HSPG2—systemic scleroderma	7.29e-05	0.00039	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EDN1—systemic scleroderma	7.01e-05	0.000375	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EDN1—systemic scleroderma	6.56e-05	0.000351	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NOS3—systemic scleroderma	6.1e-05	0.000326	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NOS3—systemic scleroderma	5.71e-05	0.000305	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL1B—systemic scleroderma	5.62e-05	0.0003	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CTGF—systemic scleroderma	5.53e-05	0.000295	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL1B—systemic scleroderma	5.26e-05	0.000281	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCL2—systemic scleroderma	4.79e-05	0.000256	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCL2—systemic scleroderma	4.48e-05	0.00024	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NOS3—systemic scleroderma	4.27e-05	0.000228	CbGpPWpGaD
Trametinib—MAP2K2—Disease—TGFB1—systemic scleroderma	4.03e-05	0.000216	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NOS3—systemic scleroderma	4e-05	0.000214	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—HSPG2—systemic scleroderma	3.91e-05	0.000209	CbGpPWpGaD
Trametinib—MAP2K1—Disease—TGFB1—systemic scleroderma	3.77e-05	0.000202	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MMP9—systemic scleroderma	3.43e-05	0.000183	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MMP9—systemic scleroderma	3.21e-05	0.000171	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CTGF—systemic scleroderma	2.97e-05	0.000159	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TGFB1—systemic scleroderma	2.83e-05	0.000151	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TGFB1—systemic scleroderma	2.64e-05	0.000141	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—NOS3—systemic scleroderma	2.41e-05	0.000129	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NOS3—systemic scleroderma	1.29e-05	6.9e-05	CbGpPWpGaD
